Crohn’s & IBD: New PubMed Studies on Cannabis Effects

New Peer‑Reviewed Insights on Cannabis and Inflammatory Bowel Disease

For patients living with Crohn’s disease or other inflammatory bowel diseases (IBD), questions about cannabis use are common. The U.S. National Library of Medicine’s PubMed database provides access to studies that explore how cannabis components interact with the gut, the immune system, and mental health. The research below summarizes findings from recent peer‑reviewed articles. These summaries are for educational purposes only; they do not replace medical advice. Always discuss cannabis use with a licensed healthcare provider.

1. Low‑Dose Cannabidiol (CBD) and Its Safety Profile

A 2025 review in the British Journal of Clinical Pharmacology examined the pharmacokinetics, pharmacodynamics, and safety of low‑dose CBD (≤2.5 mg/kg or ≤175 mg/day). The authors analyzed data from healthy volunteers and patients who received oral CBD doses up to 150 mg. They found that absorption varied across individuals, but no serious adverse events were reported at these doses. The study highlighted that low‑dose CBD is generally well tolerated, though the evidence for clinical benefit in IBD remains limited. Full study on PubMed

2. Muscone’s Rapid Antidepressant Effects in Inflammation‑Induced Depression

In a 2025 study published in Neuroscience Bulletin, researchers investigated muscone—a natural compound found in musk—using mouse models of depression triggered by peripheral inflammation (lipopolysaccharide challenge and dextran sulfate sodium‑induced colitis). Muscone administration produced rapid antidepressant‑like behavior in these mice, suggesting that inflammation‑associated mood disturbances may respond to agents that target glutamatergic signaling. The work does not directly test cannabis, but it underscores the link between gut inflammation and brain chemistry. Full study on PubMed

3. Berberine, Gut Microbiota, and the Endocannabinoid System in Colitis‑Associated Cancer

A 2024 investigation in Molecular Nutrition & Food Research explored how berberine, a plant alkaloid, modulates the gut microbiome and the endocannabinoid system (ECS) in a mouse model of colitis‑associated colorectal cancer. The authors reported shifts toward a healthier microbial profile and increased expression of ECS components after berberine treatment. These changes were associated with reduced tumor development, indicating that ECS modulation may influence disease progression. This study adds to the growing evidence that gut‑brain signaling pathways are involved in IBD pathology. Full study on PubMed

4. RGS6 Regulation of Cannabinoid Effects on Intestinal Motility

In 2025, researchers published in Pharmacological Reports an investigation into the role of regulator of G protein signaling 6 (RGS6) in the intestines. Using mouse models, they showed that RGS6 influences how cannabinoids, opioids, and serotonin receptor agonists affect gut motility and visceral pain. When RGS6 was absent, cannabinoid drugs produced stronger anti‑constipation and analgesic effects. This finding suggests that individual differences in RGS6 expression could affect how patients respond to cannabinoid therapies. Full study on PubMed

5. Mental Health in Pregnant IBD Patients

A 2024 retrospective survey in Crohn’s & Colitis 360 assessed anxiety and depression among pregnant women with IBD. The study found that these patients experienced anxiety and depressive symptoms at rates 1.5–2 times higher than the general population, especially during the first trimester. While the research did not examine cannabis use, it highlights the importance of addressing mood disorders in IBD care. Full study on PubMed

6. CB2 Receptor Activation Protects Intestinal Epithelium in Radiation Injury

In 2024, a study published in the Journal of Translational Medicine investigated the protective role of cannabinoid receptor 2 (CB2R) in radiation‑induced intestinal injury. Mouse models lacking CB2R showed greater epithelial cell loss following radiation, while treatment with a CB2R agonist preserved epithelial integrity through a β‑catenin/HoxA10 signaling loop. These results suggest that CB2R activation may support gut barrier function during inflammatory insults. Full study on PubMed

What Does This Mean for You?

Across these studies, several themes emerge:

• Low‑dose CBD appears safe, but clear clinical benefits for IBD symptoms have yet to be established.
• The gut–brain axis plays a crucial role in both inflammation and mood; targeting this pathway may offer new therapeutic angles.
• Individual genetic factors, such as RGS6 expression, could influence how cannabinoids affect gut motility and pain.
• CB2 receptor signaling protects intestinal cells during injury, pointing to potential protective mechanisms in IBD flare‑ups.

The science is still evolving, and these findings do not confirm that cannabis treats Crohn’s disease or IBD. They do, however, provide a clearer picture of how cannabis components interact with the gastrointestinal system and the immune response. If you are considering cannabis as part of your care plan, discuss the current evidence, your health history, and any medications with a licensed physician or a qualified specialty provider. Compassionate Alternative Care is here to help you navigate your medical marijuana card and answer questions about your options in Jacksonville, Florida.